An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy

[1]  Kenneth Handelman,et al.  Tolerance to Stimulant Medication for Attention Deficit Hyperactivity Disorder: Literature Review and Case Report , 2022, Brain sciences.

[2]  A. Childress.  Stimulants. , 2022, Child and adolescent psychiatric clinics of North America.

[3]  M. Bloch,et al.  The effects of stimulant dose and dosing strategy on treatment outcomes in attention-deficit/hyperactivity disorder in children and adolescents: a meta-analysis , 2022, Molecular Psychiatry.

[4]  R. Jaeschke,et al.  Methylphenidate for attention-deficit/hyperactivity disorder in adults: a narrative review , 2021, Psychopharmacology.

[5]  A. Diamond,et al.  Patients with ADHD are being overmedicated (for optimal cognitive performance) , 2019, IBRO Reports.

[6]  G. Eslick,et al.  Evaluation of Methylphenidate Safety and Maximum-Dose Titration Rationale in Attention-Deficit/Hyperactivity Disorder: A Meta-analysis. , 2019, JAMA pediatrics.

[7]  F. Nekka,et al.  A Quantitative Comparison Approach for Methylphenidate Drug Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. , 2019, Journal of child and adolescent psychopharmacology.

[8]  Naotaka Horiguchi,et al.  Pharmacokinetic-Pharmacodynamic Modeling of Brain Dopamine Levels Based on Dopamine Transporter Occupancy after Administration of Methylphenidate in Rats , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[9]  J. Newcorn,et al.  A Double-Blind, Placebo-Controlled, Phase II Study to Determine the Efficacy, Safety, Tolerability and Pharmacokinetics of a Controlled Release (CR) Formulation of Mazindol in Adults with DSM-5 Attention-Deficit/Hyperactivity Disorder (ADHD) , 2018, CNS Drugs.

[10]  S. Faraone,et al.  Model‐Based Approach for Optimizing Study Design and Clinical Drug Performances of Extended‐Release Formulations of Methylphenidate for the Treatment of ADHD , 2017, Clinical pharmacology and therapeutics.

[11]  Sara R. Jones,et al.  Differential Influence of Dopamine Transport Rate on the Potencies of Cocaine, Amphetamine, and Methylphenidate , 2014, ACS chemical neuroscience.

[12]  C. Berridge,et al.  Neurocircuitry Underlying the Preferential Sensitivity of Prefrontal Catecholamines to Low-Dose Psychostimulants , 2013, Neuropsychopharmacology.

[13]  F. Wiegand,et al.  Population pharmacodynamic modeling of various extended-release formulations of methylphenidate in children with attention deficit hyperactivity disorder via meta-analysis , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[14]  J. Buitelaar,et al.  Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate , 2011, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[15]  Richard E. Carson,et al.  Clinically Relevant Doses of Methylphenidate Significantly Occupy Norepinephrine Transporters in Humans In Vivo , 2010, Biological Psychiatry.

[16]  J. Buitelaar,et al.  Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis , 2010, European Child & Adolescent Psychiatry.

[17]  Gary M. Pollack,et al.  Opioid Tolerance Development: A Pharmacokinetic/Pharmacodynamic Perspective , 2008, The AAPS Journal.

[18]  J. Buitelaar,et al.  A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder , 2008, Biological Psychiatry.

[19]  A. Kelley,et al.  Methylphenidate Preferentially Increases Catecholamine Neurotransmission within the Prefrontal Cortex at Low Doses that Enhance Cognitive Function , 2006, Biological Psychiatry.

[20]  Martin H. Teicher,et al.  Methylphenidate blood levels and therapeutic response in children with attention-deficit hyperactivity disorder: I. Effects of different dosing regimens. , 2006, Journal of child and adolescent psychopharmacology.

[21]  H. Gu,et al.  Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs , 2006, BMC pharmacology.

[22]  Darin D Dougherty,et al.  PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate. , 2006, The American journal of psychiatry.

[23]  Yu-Shin Ding,et al.  Imaging the Effects of Methylphenidate on Brain Dopamine: New Model on Its Therapeutic Actions for Attention-Deficit/Hyperactivity Disorder , 2005, Biological Psychiatry.

[24]  A. Arnsten,et al.  Behavioral and Brain Functions , 2005 .

[25]  J. Kehr,et al.  Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain , 2004, Journal of Neuroscience Methods.

[26]  J. Swanson,et al.  Serum and brain concentrations of methylphenidate: implications for use and abuse , 2003, Neuroscience & Biobehavioral Reviews.

[27]  J. Swanson,et al.  Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: Therapeutic implications , 2002, Synapse.

[28]  P. Sachdev,et al.  How High a Dose of Stimulant Medication in Adult Attention Deficit Hyperactivity Disorder? , 2000, The Australian and New Zealand journal of psychiatry.

[29]  J S Fowler,et al.  Positron Emission Tomography Studies of Dopamine‐Enhancing Drugs , 1999, Journal of clinical pharmacology.

[30]  N. Volkow,et al.  Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. , 1998, The American journal of psychiatry.

[31]  J. Swanson,et al.  Medication treatment strategies in the MTA Study: relevance to clinicians and researchers. , 1996, Journal of the American Academy of Child and Adolescent Psychiatry.

[32]  K. Midha,et al.  Enantioselective pharmacokinetics and pharmacodynamics of dl‐thero‐mcthylphenidate in children with attention deficit hyperactivity disorder , 1992, Clinical pharmacology and therapeutics.

[33]  R. Barkley,et al.  Attention deficit disorder with and without hyperactivity: clinical response to three dose levels of methylphenidate. , 1991, Pediatrics.

[34]  Jun Yu Li,et al.  An Evaluation Approach for the Performance of Dosing Regimens in Attention-Deficit/Hyperactivity Disorder Treatment. , 2017, Journal of child and adolescent psychopharmacology.